Please login to the form below

Not currently logged in


This page shows the latest volanesorsen news and features for those working in and with pharma, biotech and healthcare.

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

roll-out stage for two new products,   Tegsedi (inotersen) for hereditary transthyretin-mediated amyloidosis and  Waylivra (volanesorsen) for familial chylomicronemia syndrome (FCS).

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...